The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer

This publication has 54 references indexed in Scilit:

• Cancer Statistics, 2007
  CA: A Cancer Journal for Clinicians, 2007
• Epidermal Growth Factor Receptor Inhibition and Non-Small Cell Lung cancer
  Critical Reviews in Clinical Laboratory Sciences, 2006
• Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study
  Clinical Cancer Research, 2005
• Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell Cancer
  Journal of Clinical Oncology, 2004
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
  Science, 2004
• Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
  New England Journal of Medicine, 2004
• Epidermal Growth Factor Receptor Signaling and the Invasive Phenotype of Ovarian Carcinoma Cells
  JNCI Journal of the National Cancer Institute, 2001
• The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma
  International Journal of Gynecologic Cancer, 2001
• Pharmacokinetics and Tolerability of the Orally Active Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Healthy Volunteers
  Clinical Pharmacokinetics, 2001
• Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
  New England Journal of Medicine, 1996